#295 Mission Slimpossible: Semaglutide for weight loss
CLINICAL QUESTION
Is semaglutide effective for weight loss?
BOTTOM LINE
Used with lifestyle changes, 2.4mg weekly subcutaneous semaglutide resulted in an average 10-15% loss in weight (10-15kg) over 68 weeks versus 2-3% (3-4kg) with placebo. Most (70-80%) semaglutide participants lost 5% or more of their body weight. About ¾ of patients experienced gastrointestinal side effects, but few stop. Weight regain occurs once the medication is stopped.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Four industry-funded, randomized, placebo-controlled trials (RCTs) of subcutaneous semaglutide 2.4mg/week for weight loss, plus lifestyle interventions (counseling, diet, and physical activity).1-4 Baseline weight ~96-105kg.
- 1961 non-diabetics.1 After 68 weeks:
- Mean weight loss: 15% of weight (15kg) versus 2% (3kg, placebo).
- Proportion who lost ≥5% weight: 86% versus 32% (placebo), number need to treat (NNT)=2.
- Lost ≥10%: 69% versus 12%, NNT=2.
- Weight loss plateaued ~week 60.
- Adverse effects:
- Gastrointestinal: 74% versus 48% (placebo), number needed to harm (NNH)=3.
- Withdrawal due to adverse effects: 7% versus 3%, NNH=25.
- RCT of semaglutide with more intensive lifestyle intervention found similar [weight loss 16% (17kg) versus 6% (6kg, placebo)].2
- Dose-finding RCT, 1210 diabetics. Given semaglutide 2.4mg/week, 1.0mg/week or placebo.3 After 68 weeks:
- Mean weight loss: 10% (2.4mg), 7% (1mg) and 3% (placebo)
- Proportion who lost ≥5% weight: 69% (2.4mg) versus 57% (1mg) versus 29% (placebo), 2.4mg versus 1mg: NNT=9.
- Adverse effects similar between doses.
- Weight maintenance RCT. 803 non-diabetics given semaglutide 2.4mg/week for 20 weeks then randomized to continue semaglutide or switch to placebo. After 48 weeks:4
- Continued semaglutide lost 8% versus 7% gain (placebo).
- 1961 non-diabetics.1 After 68 weeks:
- Weight loss with oral semaglutide studied as secondary outcome in cardiovascular disease and glucose-lowering trials. Participants weight loss was 4.6% (4.2kg) versus 0.9% (0.8kg, placebo) at 15.9 months in largest RCT.5
- High-dose semaglutide (0.4mg daily) superior to liraglutide (3mg daily) in semaglutide-sponsored RCT:
- Weight loss: 14% semaglutide (17kg) versus 8% liraglutide (8kg).
- Weight loss similar between 0.1mg daily semaglutide and liraglutide.6
- Semaglutide titration in RCTs: Every 4 weeks as tolerated.
- Semaglutide 2.4mg not currently available (Canada), but lower doses are.7
- 1mg weekly costs ~$200/month.8
Latest Tools for Practice
#363 Making a difference in indifference? Medications for apathy in dementia
In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females
How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
#361 Preventing RSV Infections in Infants
How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Very relevant to my practice
“Weight regain occurs once the medication is stopped? … even if the person maintains positive lifestyle changes?
Weight regain once medication is stopped – this information is really important when treatment is discussed with the patient.